4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($0.98), $0.25 worse than the analyst estimate of ($0.73).

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.